The US FDA is to hold a public hearing on 31st May on the safety of products containing cannabis or cannabis-derived compounds ― and stakeholders will be looking for a dividing line
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.